Optimizing disease progression study designs for drug effect discrimination
Sebastian Ueckert(Uppsala University), Andrew C. Hooker(Uppsala University), Stefanie Hennig, Joakim Nyberg(Uppsala University), Mats O. Karlsson(Uppsala University)
Cited by 7
Related Papers
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508
Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
|Pharmaceutics|2022|92
PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool
|Computer Methods and Programs in Biomedicine|2012|86
Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies
|British Journal of Clinical Pharmacology|2014|82
The lasso—a novel method for predictive covariate model building in nonlinear mixed effects models
|Journal of Pharmacokinetics and Pharmacodynamics|2007|80